Den europeiske union - maltesisk - EMA (European Medicines Agency)

teva generics b.v - zoledronic acid monohydrate - osteoporosis; osteitis deformans - bisphosphonates - it-trattament tal-osteoporosisin wara l-menopawża-taħriġ għall-adulti menat riskju akbar ta ' ksur, inklużi dawk bi trawma-ksur fil-ġenbejn. trattament ta 'osteoporożi assoċjat ma sistemiku fit-tul ta' glukokortikojdi therapyin wara l-menopawża-taħriġ għall-adulti menat żieda fir-riskju ta ' ksur. it-trattament tal-marda ta'paget ta ' l-għadam fl-adulti.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

teva b.v. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - drogi għat-trattament ta 'mard tal-għadam - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture including those with a recent low-trauma hip fracture. treatment of osteoporosis associated with long-term systemic glucocorticoid therapy: , in post-menopausal women;, in men; , at increased risk of fracture. it-trattament tal-marda ta'paget ta ' l-għadam fl-adulti.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

teva b.v. - imatinib mesilate - dermatofibrosarcoma; gastrointestinal stromal tumors; leukemia, myelogenous, chronic, bcr-abl positive - aġenti antineoplastiċi - imatinib teva b. is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. , il-pazjenti pedjatriċi b'ph+ cml fil-fażi kronika wara l-falliment ta ' l-interferon-alpha-terapija, jew fil-fażi aċċelerata jew blast crisis. , pazjenti adulti b'ph+ cml fi blast crisis. , pazjenti adulti u pedjatriċi li jkunu għadhom kif ġew dijanjostikati philadelphia chromosome positive li għandhom lewkimja limfoblastika akuta (ph+ all) integrata b'kimoterapija. , pazjenti adulti b'all rikadut jew refrattarju ph+ all bħala monoterapija. , pazjenti adulti b'mard majelodisplastiku/majeloproliferattiv (mds/mpd) assoċjat ma ' plejtlits-riċettur tal-fattur tat-tkabbir derivat (pdgfr) ġeni mill-ġdid l-arranġamenti. , pazjenti adulti b'avvanzati sindrome ipereżinofiliku (hes) u/jew lewkimja kronika eosinofilika (cel) b'fip1l1-pdgfra arranġament mill-ġdid. , l-effett ta ' imatinib fuq l-eżitu tal-trapjant tal-mudullun għadu ma ġiex determinat. imatinib teva b. is indicated for: , the treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). , il-kura awżiljarja ta 'pazjenti adulti li huma f'riskju sinifikanti ta' rikaduta wara r-risezzjoni tat-kit (cd117) pożittivi għall-gist. pazjenti li għandhom livell baxx jew l-riskju baxx ħafna ta ' rikorrenza m'għandhomx jirċievu kura awżiljarja. , il-kura ta'pazjenti adulti li ma jistax jitneħħa dermatofibrosarcoma protuberans (dfsp) u pazjenti adulti bil-rikorrenti u/jew metastatiku dfsp li mhumiex eliġibbli għall-kirurġija. , f'pazjenti adulti u pedjatriċi, l-effikaċja ta 'imatinib hija bbażata fuq globali ematoloġiċi u ċitoġenetiċi-rati ta' rispons u sopravivenza mingħajr progressjoni f'cml, fuq ematoloġiċi u ċitoġenetiċi-rati ta 'rispons f'ph+ all, mds/mpd, fuq il-rati ta' rispons ematoloġiku f'hes/cel u dwar l-objettiv tal-rati ta ' rispons fil-pazjenti adulti li ma jistax jitneħħa u/jew metastiku-gist u dfsp u dwar ir-rikorrenza-sopravivenza mingħajr progressjoni fl-adjuvant gist. l-esperjenza b'imatinib f'pazjenti b'mds/mpd assoċjati ma ' tibdil fil-ġene pdgfr hija limitata ħafna. m'hemmx provi kliniċi li juru benefiċċju kliniku jew żieda fis-sopravivenza għal dawn il-mard.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

janssen-cilag international nv - esketamine hydrochloride - mard depressiv - anti-depressanti oħrajn - spravato, f'kombinazzjoni ma 'ssri jew snri, huwa indikat għall-pazjenti adulti bil-kura reżistenti disturb dipressiv maġġuri, li ma wieġbux għal mill-inqas żewġ trattamenti differenti b'anti-depressivi fil-kurrenti moderata għal severa episodju ta' dipressjoni.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

pfizer europe ma eeig - glasdegib maleate - lewkimja, mijelojda, akuta - aġenti antineoplastiċi - daurismo is indicated, in combination with low-dose cytarabine, for the treatment of newly diagnosed de novo or secondary acute myeloid leukaemia (aml) in adult patients who are not candidates for standard induction chemotherapy.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

janssen-cilag international n.v.   - palmpalidone palmitate - skizofrenija - psikolettiċi - byannli (previously paliperidone janssen-cilag international) a 6 monthly injection, is indicated for the maintenance treatment of schizophrenia in adult patients who are clinically stable on 1 monthly or 3 monthly paliperidone palmitate injectable products (see section 5.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

novo nordisk a/s - somapacitan - tkabbir - ormoni u analogi pitwitarji u ipotalamiċi - sogroya is indicated for the replacement of endogenous growth hormone (gh) in children  aged 3  years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric ghd), and in adults with growth hormone deficiency (adult ghd).

Den europeiske union - maltesisk - EMA (European Medicines Agency)

novo nordisk a/s - semaglutide - obesity; overweight - preparazzjonijiet ta 'kontra l-ossessjoni, esklużi prodotti tad-dieta - wegovy is indicated as an adjunct to a reduced-calorie diet and increased physical activity for weight management, including weight loss and weight maintenance, in adults with an initial body mass index (bmi) of- ≥30 kg/m² (obesity), or- ≥27 kg/m² to.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

vifor fresenius medical care renal pharma france - difelikefalin - pruritus - il-prodotti terapewtiċi l-oħra kollha - kapruvia is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis (see section 5.

Den europeiske union - maltesisk - EMA (European Medicines Agency)

plusultra pharma gmbh - sirolimus - angiofibroma; tuberous sclerosis - hyftor is indicated for the treatment of facial angiofibroma associated with tuberous sclerosis complex in adults and paediatric patients aged 6 years and older.